The mainstay of treatment for claudication is reversal of risk factors, especially smoking, and the use of anti platelet drugs and possibly pentoxifylline. A major factor in the long term management is atherosclerotic involvement in other parts of the circulation resulting in a shortened life span. Treatment should be directed at the disease in general, rather than in the legs alone. Patients disabled by claudication may gain symptomatic relief with relatively low risk using balloon angioplasty or vascular reconstructive procedures.
Intermittent claudication is the most frequent clinical manifestation of atherosclerosis affecting the arteries of the lower limb. It is not uncommon in the elderly, with an incidence 2 to 3 times that of diabetes or stroke. management of claudication in the last 10 years with the advent of new therapeutic agents and interventional techniques, as well as new uses for old therapeutic agents. In this article, the treatment of intermittent claudication rather than severe ischaemia will be discussed. There have been significant advances in the
Clinical Features
Claudication is derived from the Latin term 'to limp' although this is not always a typical feature of the disorder. The characteristic complaint is of muscle pain, cramp or tiredness due to muscle ischaemia, which occurs after a reproducible amount of exercise and disappears after 1 to 5 minutes' rest in the vertical position. The site of claudication provides an indication of the level of disease with aortoiliac occlusive disease resulting in buttock, thigh and calf claudication, superficial femoral artery occlusion resulting in calf claudication and infrapopliteal disease being associated with foot discomfort on exertion. Examination of the affected patient may reveal absent pulses depending on the site of occlusion, bruits over the vascular system and trophic changes in the nails and skin of the feet and lower legs. In patients with mild claudication, a full complement of pulses may be palpable at rest, but exercise usually results in their disappearance, development of bruits and blanching of the feet.
Differential Diagnosis
Although the majority of patients complaining of claudication-like symptoms have peripheral arterial disease, there is a group of patients (5-10% of patients attending vascular clinics) in whom similar symptomatology may be in part or wholly due to non-vascular causes. These include neurospinous compression syndromes with associated back pain, paraesthesiae and postural components; diabetics and patients with peripheral neuropathy who complain of burning leg pains not usually related to exertion; venous occlusive disease resulting in bursting pain on exertion (venous claudication); and osteoarthritis of the hips and knees.
Laboratory Assessment
The vascular laboratory provides a valuable adjunct to clinical evaluation of the claudicant by measuring ankle blood pressure, recording leg artery flow wave forms and objective assessment of 405 claudication distance while walking on a treadmill. It is particularly useful in determining the role of vascular disease in the patient with atypical leg pains, and, as a baseline in the typical claudicant provides information about sites of disease, prognosis and progress.
Severe arterial occlusive disease is associated with a reduction in resting ankle blood pressure compared to brachial pressure but many patients with mild claudication have a normal resting ankle blood pressure. The test's sensitivity is markedly enhanced by determination of ankle and brachial blood pressure after a period of standardised treadmill exercise, where minimal disease resulting in symptoms is associated with a fall in ankle blood pressure returning to resting levels approximately 10 minutes after the end of exercise. Treadmill testing has the additional advantages that the time of onset of claudication may be accurately defined and the role of associated cardiorespiratory disease assessed by development of dyspnoea or angina prior to claudication.
Patients should also have laboratory determination of fasting lipids and glucose.
Natural History
The natural history of intermittent claudication has been examined in several studies (Bloor 1961; Imparato et al. 1975; le1nes et al. 1986 ) and there is agreement that the average patient has a 70 to 80% chance that their leg symptoms will improve or remain stable over a number of years with only a 20 to 30% chance of progressive deterioration. 10 to 20% of patients will eventually require reconstructive surgery and 3 to 6% come to major amputation. Claudication develops in approximately 0.22% of men per annum aged 50 to 59 years, increasing to 0.65% per annum over the age of 65 (Kannel et al. 1970) . This is comparable to the incidence of angina but occurring 10 years later. In contrast to the relatively benign course of the disease in the legs, the life expectancy of claudicants is markedly reduced compared to an age-matched population, with a 30% 5-year mortality and 60% lO-year mortality ( fig. 1 ), equating with a 10-year reduction in life expectancy. More than 50% of the excess mortality is due to coronary artery disease and it is essential that the management plan for the claudicant takes into account the widespread involvement with atherosclerosis.
Treatment
Management of the patient with intermittent claudication may be divided into 3 areas (table I). They are:
1. Local foot care; 2. General measures -treatment directed towards reducing the rate of progression of atherosclerosis in the legs and at other sites. This comprises reversal of risk factors and the use of anti platelet drugs, and should be utilised in all patients;
3. Specific measures -treatment directed towards improving the symptoms of claudication by the use of exercise programmes, drugs, balloon angioplasty and-reconstructive surgery. Thus management of claudication requires a coordinated approach involving both physicians and surgeons with expertise in the area. 
Local Foot Care
Meticulous foot care is of prime importance in the claudicant, especially in the presence of diabetes mellitus. Minor trauma which would normally heal may progress to ulceration in the ischaemic foot, thus immediate attention to cuts and blisters is critical in proper management. The feet should be kept dry and warm, and the patient should wear well-fitting shoes. Toe nails should be cut straight to avoid ingrowing and the services of a podiatrist may be required. The development of callus should be avoided with special footwear.
General Measures

Risk Factors
There are 4 major reversible risk factors for atherosclerosis involving the leg arteries. In order of importance, these are smoking, hyperlipidaemia, diabetes mellitus and hypertension.
Smoking is the most significant risk factor and 80 to 95% of claudicants have smoked. There is clear evidence that cessation of smoking is associated with improvement in walking distance, a lower rate of graft occlusion and amputation, and longer survival (Faulkner et at. 1983; Myers et at. 1978; Thomas 1981) . Patients, therefore, should be strongly encouraged to cease smoking.
Hyperlipidaemia is present in slightly less than half of patients with peripheral vascular disease. The Framingham study found that a fasting cholesterol greater than 7 mmol/L was associated with approximately twice the risk of development of claudication than lower levels (Kannel et al. 1970) . A controlled study of the effect of intensive hypolipidaemic therapy demonstrated that adequate control of serum lipids was associated with a twothirds reduction in the rate of angiographic progression of disease in the leg arteries (Duffield et al. 1983) , confirming previous uncontrolled reports. Theoretical considerations suggest that there may be specific indications for lipid-lowering drugs such as clofibrate or fish oil in claudicants. As well as its hypolipidaemic activity, clofibrate also lowers fibrinogen which is elevated in peripheral atherosclerosis, thereby raising blood viscosity. There is also some evidence that clofibrate may improve walking distance (Postlethwaite & Dormandy 1975) . Any such benefit, however, must be balanced against the possible increase in non-vascular mortality observed in one trial (Committee of Principal Investigators 1978) . Eicosapentanoic acid in fish oil lowers triglyceride and inhibits platelet function, but there have been no long term studies in claudication.
Claudicants should be screened for hyperlipidaemia and, under the age of 70 years, a fasting serum cholesterol> 5.5 mmol/L should be managed with diet with or without drug therapy. The beneficial effects of lowering cholesterol have not Hypertension is present in approximately onethird of claudicants and, as a risk factor, increases the incidence of claudication 2.5-to 4-fold (Kannel et al. 1970 ). Control of hypertension has not been associated with a lower rate of progression of atherosclerosis but treatment is important in order to reduce the risk of cerebral and renal complications and cardiac failure.
Controversy surrounds the use of {:1-blocking drugs in intermittent claudication. Although case reports initially suggested this group of agents exacerbated the symptom, a number of controlled studies examining this question have now been performed and have not demonstrated any significant clinical effect on walking distance either on commencement or cessation of {:1-blockers (Lepantalo 1985; Svendsen et al. 1986 ). Slight reductions in post-exercise calf blood flow have been reported with non-selective {:1-blockers but this is not usually seen when using {:1-blockers with intrinsic sympathomimetic activity or cardioselectivity (Lepantaio 1985; Smith & Warren 1982) . In contradistinction, Raynaud's phenomenon and cold feet are definite drug-related side effects which may necessitate withdrawal of {:1-blocker therapy. In general, there is no contraindication to treatment with {:1-blockers in patients with mild claudication and cessation of therapy is unlikely to result in clinical improvement. Nevertheless, care should be exercised when using this group of drugs, particularly in the presence of severe claudication, and non-selective {:1-blockers should be avoided.
Antiplatelet Agents
There has been increasing interest in the use of anti platelet drugs for the treatment of atherosclerosis because of the pivotal role of the platelet in the morphogenesis ofthe atherosclerotic plaque. In 2 studies in patients with peripheral vascular disease, the effect of aspirin, with or without dipyridamole, on angiographic progression of disease has been compared to placebo (Hess et al. 1985; Schoop et al. 1983) . Both studies demonstrated a significant reduction in plaque progression rate over 2 years on high-dose aspirin (> 900 mgjday) alone or in combination with dipyridamole. Since low dose aspirin more favourably affects the prostacyclinjthromboxane axis (Masotti et al. 1979) , it is my practice to use 100mg aspirin per day in all patients with intermittent claudication unless there is a contraindication. Further studies using low dose aspirin are in progress; at present, a possible additional benefit from dipyridamole is unclear.
There is also increasing evidence that antiplatelet agents may improve the long term patency rate of vascular bypass grafts in the lower limbs. This has been clearly demonstrated for coronary artery grafts using a combination of aspirin and dipyridamole or low-dose aspirin alone and some studies have demonstrated similar results in lower limb grafts (HaIjola et al. 1981) although there have been conflicting reports (Green et al. 1982) .
Specific Measures
Exercise
There is little doubt that the majority of claudicants benefit from an exercise programme. In one controlled trial, regular exercise resulted in a tripling of walking distance compared to normal activity (Larsen & Lassen 1966 ) and other uncontrolled studies have uniformly confirmed this finding. The mechanism of the exercise-induced increase in walking distance is probably an alteration in anaerobic muscle metabolism rather than an increase in collateral blood flow. Unless walking is limited by other factors such as dyspnoea or angina, regular repeated exercise to the point of claudication should be encouraged.
Vasoactive Drugs
Although vasodilator drugs (tolazoline, nicotinyl alcohol, cyclandelate) have been prescribed for treating claudication for many years, there is no evidence that they are of benefit and they may sometimes result in worsening ischaemia due to steal phenomena (Coffman 1979) .
In contrast to classic vasodilators, 2 newer agents -pentoxifYlline (oxpentifYlline) and ketanserinappear to be of some benefit in improving the symptom of claudication. PentoxifYlline 800 to 1600 mgjday, which increases red cell deformability and lowers blood viscosity and fibrinogen, has recently been approved by the American Food and Drug Administration as the first drug proven to be effective in claudication. There have been 12 double-blind placebo-controlled trials of this agent in claudicants and 10 of the 12 demonstrated a significant improvement in walking distance compared to placebo (Aviado & Porter 1984; Gallus et al. 1985; Porter et al. 1982) . The pooled weighted mean increase in claudication distance was 66% on pentoxifYlline, 22% on placebo. The effect of ketanserin, a serotonin antagonist with antiplatelet and vasodilator activity, has been studied in 5 double-blind placebo-controlled trials and a significant improvement in walking distance compared to placebo was reported in 4 of them (Bounameaux et al. 1985; Clement et al. 1987; DeCree et al. 1984) . The pooled weighted mean increase in walking distance in these studies was 65% on ketanserin vs 25% on placebo -very similar to results obtained with pentoxifYlline.
Whether the relatively small, although significant, increase in walking distance observed with these drugs will translate into significant clinical benefit in the majority of claudicants remains to be seen. It is also not known whether either of these drugs in combination with an exercise programme will result in further improvement in claudication. Further studies on these and newer agents including the PACK Trial (Prevention of Atherosclerotic Complications with Ketanserin) are awaited with interest. The calcium antagonists have not been studied methodically in the treatment of claudi-cation although there are theoretical reasons why they may be of benefit.
With attention to risk factors, exercise and judicious pharmacotherapy, a significant improvement in claudication may be expected in approximately 50% of patients. If, after 3 to 6 months of conservative therapy, there is no improvement or worsening of claudication, or the patient finds his lifestyle or employment significantly affected by the symptoms, consideration should be given to a more aggressive approach using balloon angioplasty or vascular reconstructive surgery. Both techniques require preliminary arteriography, and unless angioplasty or surgery is being considered, there is nothing to be gained and a small risk of loss of limb or life with indiscriminate arteriography, in claudicants.
Balloon Angioplasty
Angioplasty has been used successfully for both stenoses and short occlusions in the iliac and superficial femoral arteries with a low complication rate (4%) in experienced hands. In general, success rates are higher in the iliac than in more distal vessels and when stenoses rather than occlusions are dilated. Long term patency rates are somewhat difficult to determine but the average appears to be approximately 65% at 2 years for iliac angioplasty and 50% for superficial femoral angioplasty (Johnston et al. 1982) . Angioplasty is being used more frequently nowadays in the treatment of claudication at its earlier stages but the slight risk of limb loss must always be borne in mind by both patient and clinician.
Vascular Reconstructive Surgery
In patients with disabling claudication and multiple lesions, or lesions unsuitable for balloon angioplasty, modern vascular reconstructive techniques have much to offer in providing symptomatic relief. In claudication due to aortic or iliac disease, aortoiliac endarterectomy or bypass grafting using 'Dacron'are the most commonly performed procedures. Aortoiliac endarterectomy has a reported 100year patency rate of 80% (Kempczinski 1985) and the advantage that bypass grafting may be performed later if the endarterectomy occludes. It is therefore preferred in the younger patient. Aortoiliac or aortofemoral grafting has a 5-year patency of 90% and lO-year patency of75% with an operative mortality of2 to 5% (Brewster & Darling 1978; Kempczinski 1985) .
With superficial femoral artery disease -the most common cause of claudication -femoropopliteal grafting using autogenous vein, either reversed or in situ has good results in most patients with minimal mortality and a 5-year patency rate of 50 to 80% and 10-year patency of 35 to 60% (Brewster et al. 1981; Licalzi & Stansel 1982; Szilagyi et al. 1979) . Long term patency of these grafts depends principally upon the calf runoff vessels and the major reasons for graft failure are either stenoses developing within the graft or progression of atherosclerosis in inflow or outflow arteries. Artificial conduits for femoropopliteal grafts occlude with higher frequency than autogenous vein. It is important to remember that long term patency rates apply only to living patients and by 10 years, more than half of claudicants will have died.
In the presence of popliteal occlusion requiring grafting to the tibial vessels, surgery is contraindicated in the claudicant because of the less acceptable long term patency rate, although these grafts have an important place in limb salvage procedures. Some patients with infra-inguinal occlusive disease obtain symptomatic relief with common, superficial or deep femoral endarterectomy. There is no evidence that lumbar sympathectomy in isolation is of value to the claudicant.
